TABLE OF CONTENTS

Scroll or click on text or logos below to navigate to sections of the booklet. To return to the Table of Contents, click the round red TOC button at the end of each section. For optimal interactive performance, view this document in Read Mode.

- Welcome, page 3
- Agenda, page 4
- Asking Questions Online, page 5
- About NETRF, page 6
- Speaker Biographies, page 8
- Know Your NETs Glossary, page 12
- From Our Sponsors, page 23
Greetings and welcome to the 2022 KNOW YOUR NETs Virtual Patient and Caregiver Education Conference.

Response to this year’s conference has been overwhelmingly positive, and we are thrilled to bring you an informative and extensive slate of presenters discussing topics YOU told us YOU wanted to learn more about.

We are so appreciative of the outstanding group of speakers who generously gave of their time to support NETRF and our patient and caregiver community.

Questions can be submitted at any time via SLIDO.COM (see page 5) and there are four live breakout sessions scheduled during the program. Check your email for instructions about how to access these sessions, and you can also visit our homepage at NETRF.ORG and select the breakout session link there.

NETRF is grateful for our conference sponsors who have helped make this meeting possible. Please take a moment to review the educational content from our sponsors in this booklet.

Thank you for joining us today, supporting NETRF and most importantly, being an active and engaged participant to help us raise critical awareness of NETs as we Build a Better Future for NETs Patients.

Elyse Gellerman, MHS, Conference Co-Chair
CEO
NET Research Foundation

Xavier Keutgen, MD, Conference Co-Chair
Assistant Professor of Surgery
University of Chicago Medicine
# AGENDA

Program begins at 10:30AM Eastern.

<table>
<thead>
<tr>
<th>START</th>
<th>TITLE</th>
<th>PRESENTER</th>
</tr>
</thead>
</table>
| 10:30am | Conference Kickoff from Our Co-Chairs              | Elyse Gellerman  
NETRF  
Xavier Keutgen, MD  
University of Chicago Medicine |
| 10:33am | New Treatments & Trials: Targeted Therapies & Chemo | Jennifer Chan, MD, MPH  
Dana-Farber Cancer Institute |
| 10:55am | New Treatments and Trials: Radioligand Therapy/PRRT | Courtney Lawhn-Heath, MD  
University of California, San Francisco |
| 11:16am | New Treatments and Trials: Interventional Therapies | Osmanuddin Ahmed, MD  
University of Chicago Medicine |
| 11:32am | Risks and Benefits of Surgery                      | Xavier Keutgen, MD  
University of Chicago Medicine |
| 11:52am | Tumor Board: Treatment Sequencing                   | Drs. Keutgen, Andy Liao, Heath, Chan, Ahmed |
| 12:32pm | BREAKOUT SESSIONS (concurrent)                      |                                                                           |
|         | Topic 1: pNETs                                     | Mark Lewis, MD  
Intermountain Healthcare |
|         | Topic 2: SiNETs                                    | Chandrikha Chandrasekharan, MBBS  
University of Iowa |
|         | Topic 3: LungNETs                                  | Suki Padda, MD  
Cedars-Sinai Medical Center |
|         | Topic 4: Pheo Para & Genetics                      | Lauren Fishbein, MD, PhD, MTR  
CU School of Medicine |
| 1:05pm  | Patient Panel                                      | Moderated by Jessica Thomas, LCSW  
NETRF |
| 1:27pm  | The Past, Present & Future of Somatostatin Analogues | Chih-Yi (Andy) Liao, MD  
University of Chicago Medicine |
| 1:44pm  | Cumulative Treatment Toxicities                    | Thor Halfdanarson, MD  
Mayo Clinic |
| 2:05pm  | How to Read your Pathology Reports                 | Namrata Setia, MD  
University of Chicago Medicine |
| 2:37pm  | How to Read Your Radiology Reports                  | Carla Harmath, MD  
University of Chicago Medicine |
| 2:54pm  | GI Troubles, Diarrhea and Diet                      | David Richards, MD  
MD Anderson Cancer Center |
| 3:11pm  | Break Slides—Stay Tuned for Live Q and A            |                                                                           |
| 3:17pm  | Live Question and Answer Session                    | Introduced and Moderated by Dr. Keutgen |
| 3:47pm  | Conference Close and Final Comments                 | Elyse Gellerman |

Agenda subject to change
1. On your phone, tablet or computer, open your web browser and go to www.slido.com, then enter our event code: NETRF (screen 1)

2. Click on Live Interaction (screen 2). That's it! You are ready to ask questions or vote a question up (screen 3). There's no need to duplicate a question.

**DO NOT use your name. Please ask anonymously or use your initials.**

While we cannot guarantee your question will be addressed, questions with the highest numbers of votes stand a better chance of getting answered by the speaker.
The Neuroendocrine Tumor Research Foundation (NETRF) is the largest private funder of neuroendocrine tumor (NET) research. We are dedicated to funding research to discover cures and more effective treatments for neuroendocrine cancers. NETRF also works to improve the lives of patients, caregivers, and families living with neuroendocrine tumors by providing them with resources to educate and empower them in their journey.

**AN UNCOMMON AND UNDERFUNDED CANCER**

NETs are a rare cancer that can form in many different organs of the body.

NET research receives only one-tenth of one percent of government-funded grants, and is underfunded over five-fold based on its prevalence in the U.S. NETRF helps bridge this gap by funding nearly 30% of all NET research. By supporting 2.5 times more NET investigators than any other funder, NETRF has established a vibrant scientific community dedicated to understanding NETs and its treatment.

175K Americans affected. 12K New diagnoses in the U.S. each year. 50% Misdiagnosed first with another condition. 5 Average number of years from onset of symptoms to diagnosis.

150+ published research manuscripts

$34.3 million in funded research

115 grants awarded 125 investigators funded

$0.90 of each $1.00 supported research and education in 2021

Funded research in 15 countries + 17 U.S. states
Being diagnosed with an uncommon cancer like a neuroendocrine tumor (NET) can feel isolating or overwhelming. NETWise, a podcast about neuroendocrine cancer, is here to help patients and caregivers navigate the world of NETs.

Listen in as the NET Research Foundation (NETRF) speaks with experts and patients who will help us to understand NET diagnosis, treatment, and everything in between. NETWise is for everyone, from newly diagnosed patients to longtime survivors, as well as caregivers and family members.

This is your guide to learning, listening, knowing, and being NETWise.

If you’re interested in participating in one of our upcoming NETWise podcasts as a patient, caregiver or clinician, please email info@netrf.org.

How to find NETWise, a New Way to Learn about NETs

netrf.org/podcast
NETRF is pleased to offer an updated Neuroendocrine Cancer Guide for Patients and Families.

This 2022 edition includes 16 additional pages of information and graphics to help patients and families understand neuroendocrine cancer.

To order your copy visit, netrf.org/for-patients/guide or scan the QR code here:
Osmanuddin Ahmed, MD
University of Chicago Medicine
Dr. Ahmed is an associate professor of Radiology at University of Chicago Medicine and is board certified in Diagnostic and Interventional Radiology. He received his medical degree from University of Illinois at Chicago and completed a vascular and interventional radiology fellowship at Stanford Hospital.

Jennifer Chan, MD, MPH
Dana-Farber Cancer Institute
Dr. Chan is an Associate Professor of Medicine at Harvard Medical School and senior physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA. She focuses her clinical practice on the care of patients with neuroendocrine tumors and gastrointestinal cancers. She is the Director of the Program in Neuroendocrine and Carcinoid Tumors and Clinical Director for the Gastrointestinal Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center. She has been principal investigator of multiple clinical trials investigating novel therapies for neuroendocrine tumors and studies examining factors associated with clinical outcomes in patients with neuroendocrine tumors.

Chandrikha Chandrasekharan, MBBS
University of Iowa
Dr. Chandrasekharan is a Clinical Assistant Professor at University of Iowa and holds a combined position at Veterans Affairs Hospital at Iowa City as Section Chief of Medical Oncology. After completing medical oncology fellowship, she pursued advanced oncology training in gastrointestinal malignancies at Mayo Clinic. In addition to Oncology, her training in Palliative Medicine has equipped her with skills to integrate palliative care and provide effective symptom management in her practice. Her clinical practice and research interests include all gastrointestinal malignancies with a focus on neuroendocrine tumors. As part of the Neuroendocrine Tumor SPORE, Specialized Program of Research Excellence, the only one for this cancer in the country at University of Iowa, she has been actively engaged in multiple clinical trials and research projects focusing on patients living with NETs.

Lauren Fishbein, MD, PhD, MTR
University of Colorado School of Medicine
Dr. Fishbein is physician scientist and Associate Professor of Medicine at the University of Colorado, Division of Endocrinology, Metabolism and Diabetes. She has a strong interest in personalized medicine, including understanding the impact of germline predisposition for endocrine tumor syndromes. Her research program focuses on investigating the interplay between somatic and germline genetics focused on pheochromocytoma/paraganglioma. Dr. Fishbein has chaired several national and international committees, including for the Endocrine Society, the North American Neuroendocrine Tumor Society, and the American-Australian-Asian-Adrenal Alliance (A5) research consortium’s Pheo/Para Working Group. She is currently a volunteer member of the Medical Advisory Board for the Pheo Para Alliance.

Thor Halfdanarson, MD
Mayo Clinic
Dr. Halfdanarson is a professor of Oncology at the Mayo Clinic College of Medicine and Science and a consultant in Medical Oncology at the Mayo Clinic. He specializes in GI oncology with a focus on NETs, staffs the Unknown Primary Clinic, serves as the chair of the GI Tumor Group and is the co-chair of the Pancreatic/Neuroendocrine Tumor Board. Dr. Halfdanarson is a member of the NCCN guidelines panel for NETs, the past chair of the Guidelines and Publications Committee of NANETS, is the current secretary and on the Board of Directors of NANETS, and is a faculty member for the European Society of Medical Oncology for neuroendocrine and endocrine neoplasms and cancers of unknown primary.
Carla Harmath, MD  
*University of Chicago Medicine*  
Dr. Harmath is an Associate Professor of Radiology and is the section chief of abdominal radiology at The University of Chicago Medicine. She has a fellowship in abdominal imaging with an emphasis in MRI. Her interests include oncologic imaging, transplant imaging, education and diversity in medicine. Her goal as a radiologist is the adequate utilization of medical imaging, optimizing care and treatment planning for the patients. She thrives in a collaborative multidisciplinary environment with a focus on each patient’s best interest and evidence-based care.

Xavier Keutgen, MD, FACS  
*University of Chicago Medicine*  
Dr. Keutgen is a surgical oncologist with particular expertise in treating neuroendocrine, thyroid, parathyroid and adrenal tumors. He is the director of the University of Chicago Neuroendocrine Tumor Center and works closely with multidisciplinary team that specializes in NETs. Dr. Keutgen, a Belgian native, received his medical degree from the University of Heidelberg (Germany), and completed his residency at New York Presbyterian Hospital-Weill Cornell Medical Center and fellowships at the University of Zurich (Switzerland) and the National Cancer Institute (NIH).

Courtney Lawhn Heath, MD  
*University of California, San Francisco*  
Dr. Lawhn Heath is an Assistant Professor of Molecular Imaging and Therapeutics in the Department of Radiology and Biomedical Imaging at the University of California San Francisco (UCSF), where she also serves as Associate Program Director of the UCSF Molecular Imaging and Therapeutics fellowship programs. In 2021, she was named “One to Watch” by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) on their list of 30 early career professionals who have set themselves apart as future thought leaders in nuclear medicine and molecular imaging. Her research interests include somatostatin receptor PET, targeted radionuclide therapy, and the molecular imaging of breast and prostate cancer.

Mark Lewis, MD  
*Intermountain Healthcare*  
Dr. Lewis is the director of gastrointestinal oncology at Intermountain Healthcare. He received his medical degree, completed his internal medicine residency, and served as chief resident at Baylor College of Medicine in Houston, Texas. After completing a hematology/oncology fellowship at the Mayo Clinic in Rochester, Minnesota, where he served as chief fellow, he returned to Houston where he worked at The University of Texas MD Anderson Cancer Center with a dual appointment in general & gastrointestinal medical oncology before assuming his current position in 2016.

Chih-Yi (Andy) Liao, MD  
*University of Chicago Medicine*  
Dr. Liao is an Assistant Professor of Medicine at University of Chicago. He is a medical oncologist and clinical investigator who specializes in treating gastrointestinal neuroendocrine tumors and hepatobiliary cancers. He serves as the principal investigator of many clinical trials for these cancers and is the Associate Director of University of Chicago’s Gastrointestinal Oncology Program and the Co-Director of the Neuroendocrine Tumor Program.
**Sukhmani Padda, MD**  
*Cedars-Sinai Cancer Institute*  
Dr. Padda is the director of Thoracic Medical Oncology at Cedars-Sinai Medical Center. She completed an internal medicine residency and hematology/oncology fellowship at Stanford University in 2014. After serving as faculty at Stanford University, she joined Cedars-Sinai Medical Center Division of Oncology, Department of Medicine in 2021. In collaboration with multidisciplinary clinical experts and scientists, Dr. Padda’s goals are focused in expanding clinical trials and translational research in thoracic oncology. Dr. Padda’s research focus includes examining novel targeted therapeutics in genomic subsets of non-small cell lung cancer (e.g., EGFR, KRAS) and conducting clinical research in lung neuroendocrine tumors and thymic malignancies.

**David Richards, MD**  
*MD Anderson Cancer Center*  
Dr. Richards is a physician in the Department of Gastroenterology, Hepatology & Nutrition. His clinical interests are in GI motility disorders, small bowel disorders, GI bleeding, and gastrointestinal immunology. His research interests are in the management of dysphagia and particularly the management of esophageal strictures, management of motility disorders, and GI immunology.

**Namrata Setia, MD**  
*University of Chicago Medicine*  
Dr. Setia is Associate Professor in the Department of Pathology at University of Chicago. She is actively involved in educational activities and committees of the United States and Canadian Academy of Pathologists and College of American Pathologists. Her clinical practice is focused on the diseases of gastrointestinal tract and pancreas. Her clinical interests include translational applications of molecular methods to the non-neoplastic and neoplastic diseases of the pancreas and gastrointestinal tract. She has avidly published in her areas of interest and has been invited to lectures both nationally and internationally.

**Jessica Thomas, LCSW**  
*NETRF Director of Patient Education*  
Ms. Thomas brings more than 17 years of experience as a clinical social worker specializing in helping patients and caregivers within the areas of neurology, oncology and chronic illness. She has held management and leadership roles in non-profit and for-profit settings. She has experience in different capacities ranging from program development and management, patient education, and professional outreach to marketing and community engagement. She has participated in healthcare advocacy initiatives at the grassroots, state and federal levels.
5-hydroxyindoleacetic acid (5-HIAA) test
A test that measures the amount of 5-HIAA in the urine. 5-HIAA is a substance that is broken down, or metabolized, from serotonin. It’s often done to detect certain tumors in the digestive tract (like carcinoid tumors) and to track a person’s condition.

18F-dihydroxy-phenylalanine
A radioactive substance or tracer. It’s used in PET scans to detect the location of NETs. It can also be called fluorodopa or 18F-DOPA.

ACE Inhibitor
An ACE inhibitor is a drug that’s used to lower blood pressure. The full name is angiotensin-converting enzyme inhibitor.

Acute
Acute symptoms are symptoms or signs that begin and worsen quickly.

Adenocarcinoma
An adenocarcinoma is a cancer that begins in glandular (or secretory) cells. Glandular cells can be found in a tissue that lines certain internal organs. They make and release substances in the body, such as mucus, digestive juices, or other fluids. Most cancers of the breast, pancreas, lung, prostate, and colon are adenocarcinomas.

Adenoma
A tumor that is not cancer. It starts in gland-like cells of the epithelial tissue (a thin layer of tissue that covers organs, glands, and other structures in the body).

Adjunctive therapy
A supporting treatment used together with the primary treatment. Also called adjunct therapy.

Adjuvant therapy
Cancer treatment that is given after the primary treatment to lower the risk of cancer coming back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy.

Abdomen
The abdomen is the belly area between the chest and pelvis. It contains the pancreas, stomach, intestine, liver, gallbladder, and other organs.

Ablation
In medicine, ablation is the removal of a body part, tissue, or its function. The procedure may be done by surgery, hormones, drugs, radiofrequency, heat, or other methods.
Adrenal glands
Two small organs near the kidneys that release hormones. These hormones help control heart rate, blood pressure, and other important body functions. Also called suprarenal gland.

Adrenaline
A hormone and neurotransmitter. Also called epinephrine.

Adverse events
An unexpected medical problem that happens during treatment with a drug or other therapy. Adverse events may be mild, moderate, or severe, and may be caused by something other than the drug or therapy being given. Also called a side effect or adverse effect.

Analgesic
A drug that reduces pain, like aspirin, acetaminophen, or ibuprofen.

Analog
In chemistry, a substance that is similar, but not identical, to another.

APUDoma
An APUDoma is an endocrine tumor that rises from an APUD cell (amine precursor uptake and decarboxylation).

Atrophic Gastritis
Atrophic gastritis develops when the lining of the stomach has been inflamed for several years. The inflammation is most often the result of a bacterial infection caused by the H. pylori bacterium. The bacteria disrupt the barrier of mucus that protects the stomach lining from acidic juices that help with digestion. If it’s not treated, the infection can gradually destroy the cells in the stomach lining.

Biomarker
A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Bone scan (Bone scintigraphy)
A procedure to check for abnormal areas or damage in the bones. A bone scan may be used to diagnose bone tumors, or cancer, that has spread to the bone. It may also be used to help diagnose fractures, bone infections, or other bone problems. Also called bone scintigraphy.

Bronchial NETs
Bronchial NETs are neuroendocrine tumors that develop in the lungs. There are two types depending on where they occur. The first is central bronchial. They are tumors located in the trachea (windpipe) and around the main central area of the lungs. The second is peripheral bronchial, located in the outer areas of the lungs.

Bronchoscope
A thin, tube-like instrument that is used to examine the inside of the trachea and bronchi (air passages that lead to the lungs), and lungs. A bronchoscope has a light and a lens for viewing, and may also have a tool to remove tissue.

Bronchoscopy
A nonsurgical procedure that looks inside the airways of the lungs by using a bronchoscope.

Caregiver
A family member or paid helper who regularly looks after a child or a sick, elderly, or disabled person.

Carcinogenesis
The process by which normal cells transform into cancer cells.

Carcinoid crisis
Carcinoid crisis is when all of the symptoms of carcinoid
Carcinoid syndrome occurs at the same time. It is generally found in people with carcinoid tumors. The crisis may occur suddenly, or it may be associated with stress, chemotherapy, or anesthesia. It’s characterized by an abrupt flushing of the face, and sometimes upper body. Severe falls in blood pressure and bronchospasm with wheezing can (infrequently) occur.

**Carcinoid syndrome**
Carcinoid syndrome is a group of symptoms associated with functional carcinoid tumors, like diarrhea or flushing.

**Carcinoid tumors**
Slow-growing tumors usually found in the gastrointestinal system (most often in the small intestine and rectum), and sometimes in the lungs or other sites. Carcinoid tumors may spread to the liver or other sites in the body, and they may secrete substances such as serotonin or prostaglandins that cause carcinoid syndrome.

**Carcinomas**
A type of cancer that begins in the skin or in the tissues that line or cover internal organs.

**Catecholamines**
A type of neurohormone (a chemical made by nerve cells and used to send signals to other cells). Catecholamines are also a collective term for the hormones epinephrine, norepinephrine, and dopamine.

**Chemotherapy**
Anti-cancer drugs given either by mouth or by injection into a vein or muscle to kill cancer cells.

**Cholelithiasis**
Cholelithiasis is the medical term for gallstones; hard, crystal-like lumps that form out of a fluid called bile.

**Chromogranin A (CgA)**
A protein found inside neuroendocrine cells that can be released, along with other hormones, into the blood. It can be found in higher than normal amounts in patients with certain neuroendocrine tumors, small cell lung cancer, and prostate cancer. Measuring the amount of chromogranin A in the blood can help diagnose cancer or other conditions.

**Colon**
The longest part of the large intestine, a tube-like organ connected to the small intestine at one end, and the anus at the other. The colon removes water, some nutrients, and electrolytes from partially digested food. The remaining material (solid waste called stool) moves through the colon to the rectum, and leaves the body through the anus.

**Colonoscopy**
A test that examines the inside of the colon (gut). During this test, a colonoscope is inserted into the anus and passed up inside the colon. The colonoscope, a thin, tube-like instrument, has a very small light and video camera at the end for viewing.

**Computed tomography (CT) scan**
A CT scan is an imaging method that uses X-rays to create pictures of cross-sections of the body.

**Crohn’s disease**
Crohn’s disease is one of a group of diseases called inflammatory bowel disease. It causes inflammation of the digestive system. It can affect any area from the mouth to the anus. Crohn’s disease can increase the risk of colorectal cancer and small intestinal cancer. Symptoms include fever, diarrhea, stomach cramps, vomiting, and weight loss.

**Cryoablation**
A procedure that involves freezing cancer cells to kill them. A thin surgical instrument called a cryoprobe is inserted through the skin and directly into the tumors to freeze them. Also known as cryotherapy or cryosurgery.

**Cryoprobe**
A surgical instrument used to apply extreme cold to tissues.

**Cryosurgery**
Also known as cryoablation, a procedure that involves freezing cancer cells to kill them. A thin surgical instrument called a cryoprobe is inserted through the skin and directly into the tumors to freeze them. Also known as cryotherapy or cryosurgery.

**Cytotoxic agent**
Any substance that kills cells, including cancer cells. These substances can help stop cancer cells from dividing and growing, and may even cause tumors to shrink in size.
Deep subcutaneous injection (subcutaneous injection)
A deep subcutaneous injection is a method of administering medication. Subcutaneous means under the skin. In this type of injection, a short needle is used to inject a drug into the tissue layer between the skin and the muscle. Also known as subcutaneous injection.

Debulking
A type of surgery used to remove as much of the cancer as possible to help make chemotherapy or radiation possible or more effective.

Dietitian
A healthcare professional who is an expert in diet and nutrition. A dietician can advise patients on how to eat healthily.

Differentiation
In cancer, refers to how mature (developed) the cancer cells are in a tumor. Tumor cells that are differentiated can resemble normal cells. They tend to grow and spread at a slower rate than undifferentiated or poorly differentiated tumor cells which grow uncontrollably.

DNA
Molecules inside cells that carry genetic information and pass it from one generation to the next. The full name is deoxyribonucleic acid.

Dopamine
A hormone and neurotransmitter (messenger) released by the nervous system.

Duodenum
The first part of the small intestine, attached to the stomach. This is the part food enters immediately after it leaves the stomach. It helps digest food further and absorb nutrients and water for the body.

Dysplasia
Cells that may look abnormal under a microscope but are not cancer.

Echocardiogram
An imaging test that uses ultrasound to produce moving images of the heart and blood flow through the heart’s valves and structures. Also called a cardiac echo or simply an echo.

Efficacy
How well a treatment works. The measurements that determine efficacy are decided in advance of a clinical trial and are constantly monitored as the trial progresses.

Endocrine cancer
Cancer that occurs in endocrine tissue; the tissue in the body that secretes hormones.

Endocrine system
The endocrine system consists of hormone-producing cells. Hormones are chemical substances that are carried through the bloodstream. They have a specific regulatory effect on the activity of other organs and cells in the body. The neuroendocrine system is part of the endocrine system. The endocrine system controls growth, sexual development, sleep, hunger, and the way the body uses food.

Endocrinologist
A doctor that specializes in diagnosing and treating conditions caused by hormonal or endocrine imbalances in the body.

Endoscope
A long, thin, flexible tube that has a light and a video camera at the end and is inserted into the body via the mouth. They can also be used to collect a sample of tissue (biopsy) for further examination.

Endoscopy
A nonsurgical procedure that is used to look inside a person’s digestive tract using an endoscope.

Epinephrine
Epinephrine, also called adrenaline, is a naturally occurring hormone. It’s one of two chemicals released by the adrenal gland (the other is norepinephrine). Epinephrine increases the speed and force of heartbeats and thereby the work that can be done by the heart. Epinephrine has
been produced synthetically as a drug since 1900. It remains the drug of choice for treatment of anaphylaxis, life-threatening allergic reactions.

Fine-needle aspiration
A procedure that removes tissue samples with a very thin needle.

First-line therapy
The first drug, or set of drugs, given to treat cancer.

Fluorodeoxyglucose
A radioactive substance or tracer that is used in a PET scan to help identify the presence of certain tumor types within the body. It measures how much energy (glucose) the tumors are using. Usually abbreviated to FDG.

Flushing (carcinoid flushing)
A reddening of the skin. Episodes of severe flushing can be triggered by exercise, alcohol, stress, and certain foods in 75% of patients with carcinoid syndrome. Carcinoid syndrome occurs in about 10% of patients with carcinoid tumors. With time, flushing may appear without provocation. The character of the flush differs depending upon the site of origin of the tumor.

Functioning tumors
Neuroendocrine tumors (NETs) that make an excess of hormones and cause signs and symptoms. Also known as functional tumors.

Fusion scan (MIBG, OctreoScan or other scans)
The fusion scan electronically fuses, or combines images from an OctreoScan, MIBG scan (or any other PET scan) with those of a CT scan. Together, they render a final image that may be superior to those of the individual scans.

Gallbladder
The pear-shaped organ found below the liver. Bile is concentrated and stored in the gallbladder.

Gallium-68
A radioactive substance or tracer that can be combined with a protein that targets somatostatin receptors. When injected into the body, it can be used to identify specific neuroendocrine cancer cells during a PET scan.

Gallstone
Solid material that forms in the gallbladder or common bile duct. Gallstones are made of cholesterol or other substances found in the gallbladder. They may occur as one large stone or as many small ones, and vary from the size of a grain of sand to a golf ball.

Gastrin
A hormone released after eating from special cells in the lining of the stomach. Gastrin causes the stomach to release an acid that helps digest food.

Gastritis
Gastritis is an inflammation, irritation, or erosion of the lining of the stomach. Common symptoms may include appetite loss, indigestion, black stools, nausea, and vomiting. Some people may not experience symptoms.

Gastroenterologist
A doctor that specializes in diagnosing and treating disorders of the gastrointestinal tract (digestive system). This can include the food pipe (esophagus), stomach, liver, and gut (intestines).

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
A rare type of tumor that can form in the pancreas or in other parts of the gastrointestinal tract, including the stomach, small intestine, colon, rectum, and appendix. GEP-NETs usually form in cells that secrete hormones. Some of these tumors make extra amounts of hormones (and other substances) that can cause signs and symptoms of disease, including a condition called carcinoid syndrome. GEP-NETs may be a benign (noncancerous) or malignant (cancer).
Gastrointestinal NETs (GI-NETs)
Previously called carcinoid tumors, GI-NETs are the most common type of neuroendocrine tumors (NETs). They are found in the gastrointestinal (GI) tract, and include tumors that develop in the bowel, stomach, or food pipe (esophagus). Also called gastric NETs or GI-NETs.

Gastrointestinal tract
The organ system responsible for consuming, digesting, absorbing nutrients, and getting rid of food (waste). The gastrointestinal tract includes the mouth, throat, esophagus, stomach, small and large intestine, rectum, and anus.

Gastroscopy
An examination of the inside of the stomach by using a flexible fiberoptic tube (a gastroscope). The gastroscope is passed through the mouth and esophagus and into the stomach.

Glucagon
A hormone produced by the pancreas that helps to increase blood sugar (glucose).

Grade
A description of how cancer cells and surrounding tissues look under a microscope, and how quickly they are likely to grow and spread. Grades are used to help plan treatment and determine prognosis. Also called histologic grade and tumor grade.

Histamine
A type of neurotransmitter that has many effects in the body. It’s a part of the body’s immune response and is released during an allergic reaction. It causes small blood vessel to widen and become leaky, which can cause tissues to swell. Histamine can also cause smooth muscles to contract (tighten), gastric acid to be made, and the heart rate to increase.

Hormone
Chemical substances that are carried through the bloodstream and have specific regulatory effect on the activity of other organs or cells in the body.

Inflammatory bowel disease (IBD)
A disorder in the intestine. Signs and symptoms can include abdominal pain, bloating, and changes in bowel habits, like constipation, diarrhea, or both. Also called irritable bowel syndrome.

Irritable bowel syndrome (IBS)
A disorder in the intestine. Signs and symptoms can include abdominal pain, bloating, and changes in bowel habits, like constipation, diarrhea, or both. Also called irritable bowel syndrome.

Ileum
The last section of the small intestine that attaches to the large intestine.

Hematology
The science that studies the blood.

Hepatic
Having to do with the liver. For example, the right and left hepatic ducts.

Hepatic chemoembolisation
A therapeutic method used to treat primary liver tumors and cancer tumors that have spread to the liver (metastatic liver tumors).

Immunotherapy
An artificial stimulation, or imitation, of the body’s immune system to treat or fight disease.

Injection
Pushing medication into the body through the use of a syringe or needle. There are different types of injections. Intramuscular (IM) injections: Into the muscle. Intravenous (IV) injections: Into the vein. Subcutaneous (SC) injections: Into the fatty tissue under the skin.

Insulin
A hormone made by the pancreas that helps maintain normal blood sugar levels.
Interferon
A substance that can improve the body’s natural response to infections and other diseases. Interferons help stop cancer cells from forming new cancer cells and can slow down the growth of tumors. The body normally produces interferon. It can also be made in the laboratory to treat cancer and other diseases.

Intervention
The treatment, procedure, or other action taken to prevent or treat disease, or help improve health.

Interventional study
A clinical trial in which researchers assign one or more interventions to a group of suitable participants. The results of this study can help provide researchers with information about cause and effect.

Intramuscular injection
An injection that is delivered directly into the muscle.

Intraoperative radiation therapy (IORT)
Radiation therapy that is given during surgery.

Irradiation
A treatment method that delivers radiotherapy to the whole body. It uses high-energy radiation to destroy cancer cells and shrink tumors. Also called radiation therapy.

Jejunum
The middle section of the small intestine (between the duodenum and ileum).

Ki-67 index
The Ki-67 index measures how much Ki-67 protein is present in cancer cells. Ki-67 is a protein used to diagnose and assess the prognosis of tumors, including neuroendocrine tumors (NETs).

Linear accelerator
A machine that uses electricity to form a stream of fast-moving subatomic particles. This creates a high-energy radiation that may be used to treat cancer.

Localized
A tumor contained in one area of the body.

Lung function tests
Tests that look at how well the lungs work by measuring how much air a person can exhale after taking in a deep breath. Also called pulmonary function tests.

Lutetium-177
A radioactive substance that can be combined with a protein to target somatostatin receptors. It releases radiation and kills the tumor cells.

Magnetic resonance imaging (MRI) scan
An MRI uses a large magnet and radio waves to look at organs and structures inside your body.

Malignant tumors
Malignant tumors are made up of cells that grow out of control. Cells in these tumors can invade nearby tissues and spread to other parts of the body.

Metastasis
A process that describes how cancer cells spread from one part of the body to another.

Metastasize
To spread from one part of the body to another.

MIBG scan
An imaging test that uses radiopharmaceutical metaiodobenzylguanidine (MIBG) to help locate and diagnose certain types of cancer in the body.
Multidisciplinary team
Healthcare professionals from various clinical areas who help advise patients about the different aspects of NETs care.

Multiple endocrine neoplasia (MEN)
A rare, genetic condition that causes tumors to develop in endocrine glands, most common in the parathyroid glands, pituitary gland, and the pancreas. Also known as MEN (acronym).

Neuroendocrine cells
Cells that release hormones into the blood in response to a signal from the nervous system.

Neuroendocrine tumors (NETs)
A tumor derived from neuroendocrine cells. Neuroendocrine cells release a hormone in response to a signal from the nervous system. Neuroendocrine tumors can secrete an excess of hormones and cause a variety of symptoms. Examples of neuroendocrine tumors are carcinoid tumors, islet cell tumors, medullary thyroid carcinoma, and pheochromocytoma.

Neuroendocrine system
Having to do with interactions between the nervous system and endocrine system. The neuroendocrine system is comprised of cells that are a cross between traditional hormone-producing cells and nerve cells.

Palliative Care Team
A team of specialized doctors, nurses, and other healthcare professionals who are trained to provide supportive care, such as pain relief to people with long-term terminal illnesses, particularly during the last days of life.

Pancreas
A pear-shaped gland located in the abdomen between the stomach and the spine. It is about six inches long and releases enzymes that help the body digest food. The pancreas also produces insulin, which helps control the amount of sugar in the blood.

Pancreatic neuroendocrine tumor (pNETs)
Pancreatic neuroendocrine tumors (pNETs) are tumors that form in hormone-making cells (islet cells) of the pancreas. These include functioning and non-functioning tumors.

Pancreatic polypeptide
A hormone produced by the pancreas. Levels of pancreatic polypeptides are high in the blood of people with pancreatic NETs (pNETS). Blood levels can therefore be used to help in the diagnosis of, and monitor, pNETs.

Pathologist
A physician who identifies diseases and conditions by studying the structure and characteristics of cells and tissues.

Peptic ulcer disease
Peptic ulcer disease involves sores that develop in the lining of the stomach, lower esophagus, or small intestine. Also known as stomach ulcers.

Peptide receptor radionuclide therapy (PRRT)
A form of molecular targeted therapy which is performed by using a small peptide that is coupled with a radionuclide emitting beta radiation. PRRT is an innovative nuclear medicine therapy for the systemic treatment of tumors, including metastasized neuroendocrine tumors.

Oncology
The study and treatment of cancer. Doctors who specialize in oncology are called oncologists.

Oncologist
A doctor who specializes in oncology.
Percutaneous alcohol injection
A therapy involving the injection of pure alcohol through the skin, directly into cancerous tumors in the liver to kill cancer cells. A CT scan or an ultrasound guides needle into the tumor. Used to treat liver cancer. Also known as a percutaneous ethanol injection (PEI).

Placebo
A placebo is a substance that has no effect on the disease, but is used as a control to compare the effects of an actual treatment. It could be a pill, a shot, or some other type of “fake” treatment. What all placebos have in common is that they do not contain an active substance meant to affect health.

Positron emission tomography (PET)
A PET scan is an imaging technique that can show how body tissues are working, as well as what they look like. It can help diagnose and assess the severity of a cancer. For this scan, a radioactive tracer is injected into a vein.

Primary Care Physician (PCP)
A primary care physician (PCP) or general practitioner (GP) is a medical doctor who diagnoses and treats all types of medical conditions. GPs are often the first healthcare professional a patient will see before they are referred for specialist care. A practice nurse works alongside the GP to assess, screen, treat, and educate patients on health, and help monitor those with long-term conditions.

Primary site
The place in the body where a tumor starts.

Primary treatment
The main, or first, treatment used by the healthcare provider to treat cancer in the body.

Primary tumor
The original, or first, tumor in the body. Cancer cells can spread from a primary tumor to other parts of the body and form secondary tumors. This process is called metastasis.

Probiotic supplements
Probiotic supplements are live bacteria and yeasts that are good or helpful for your gastrointestinal (digestive) system.

Prognosis
A medical prediction about the probable cause and outcome of a disease.

Proliferative index
A measure of the number of cells in a tumor that are dividing (proliferating).

Prophylaxis
Preventative treatment or action

Radiation
The use of high-energy X-rays to kill cancer cells.

Radiation therapy
A procedure involving the use of high-energy radio waves, such as X-rays, gamma rays, electron beams, or protons, to destroy or damage cancer cells. Also called radiotherapy, irradiation, or X-ray therapy.

Radioembolization
Radioembolization uses radiation to treat neuroendocrine tumors (NETs) that have developed in the liver. It uses a thin tube to inject radioactive substance into the blood vessel that goes to the liver. The radioactive substance destroys the blood vessels where the tumor grows killing the cancer cells. Also called intra-arterial brachytherapy.

Radiofrequency ablation (RFA)
Radiofrequency ablation (RFA) uses heat made by radio waves to kill cancer cells. RFA is given using a probe (electrode) that is injected through the skin and into the tumor. The electrical current from the probe heats the cancer cells to high temperatures and can destroy them.

Radiologist
A medical doctor who specializes in diagnosing and treating disease and injury through the use of medical imaging techniques, like X-rays, and ultrasound.

Radionuclide
A radionuclide (sometimes called a radioisotope or isotope) is an unstable form of a chemical element that releases radiation as it breaks down and becomes more stable.
Radiotherapy
A procedure involving the use of high-energy radio waves, like X-rays, gamma rays, electron beams, or protons, to destroy or damage cancer cells. Also called irradiation or X-ray therapy.

Resection
The surgical removal of an organ or structure, such as a tumor.

Safety
A measure of a participant's health and well-being during and after a clinical trial. Safety is the top priority in the clinical trials. That's why members of the research team closely monitor changes in participants' health throughout the trial.

Scintigraphy
An imaging test that produces two-dimensional images of the distribution of radioactivity in tissues after the internal administration of a radiopharmaceutical imaging agent.

Secondary cancer
A tumor formed from cancer cells that spread from a primary tumor to other parts of the body. The secondary tumor is the same type of cancer as the primary tumor. Also known as a secondary tumor or metastasis.

Serotonin
A hormone and neurotransmitter that is found in many tissues of the body.

Small bowel capsule endoscopy
A way to record images of the gastrointestinal (digestive) system. It involves swallowing a small capsule about the size and shape of a pill. The capsule contains a very small video camera that takes pictures of the inside of the gut.

Somatostatin
Somatostatin is a polypeptide type of hormone usually found in the hypothalamus and inhibits the secretion of other hormones including growth hormone, insulin, and gastrin.

Somatostatin analog (SSA)
Medication that copies or mimics the action of the hormone somatostatin. Somatostatin analogs may reduce the symptoms of neuroendocrine tumors (NETs) by stopping the body from making too many hormones. They may help slow tumor growth. Given by injection.

Somatostatin receptor scintigraphy (SRS)
A type of radionuclide scan used to find carcinoid and other types of tumors. Radioactive compound that targets somatostatin receptors is injected into a vein and travels through the bloodstream. The radioactive compound attaches to tumor cells that have receptors for somatostatin. A radiation-measuring device makes pictures showing where the tumor cells are in the body. This procedure is also called somatostatin receptor scintigraphy (SRS).

Sonography
A procedure that uses high-energy sound waves (ultrasound) to look at tissues and organs inside the body. Ultrasound is also known as sonography.

Subcutaneous injection (deep subcutaneous injection)
A subcutaneous injection is a method of administering medication. Subcutaneous means under the skin. In this type of injection, a short needle is used to inject a drug into the tissue layer between the skin and the muscle. Also known as deep subcutaneous injection.

Surgeon
A highly skilled doctor who performs operations, such as the removal of neuroendocrine tumors (NETs).

Surgery
Surgery for neuroendocrine tumors (NETs) involving the physical removal of tumors.

Targeted cancer therapies
Drugs or other substances that block the growth, development, and spread of cancer cells. These treatments are also known as molecularly targeted therapies.
Thyroid
A gland that is part of the endocrine system and regulates hormones in the body. The thyroid absorbs iodine from the bloodstream to produce thyroid hormones. The thyroid hormones regulate metabolism in the body.

Transarterial chemoembolization (TACE)
A procedure that blocks (embolizes) the blood supply to a tumor and administers chemotherapy directly into the tumor. TACE is used to treat liver cancer. It’s also called chemoembolization or hepatic artery embolization (HAE).

Ultrasound scan
An ultrasound scan is a procedure that uses high-energy sound waves (ultrasound) to look at tissues and organs inside the body. Ultrasound is also known as sonography.

Undifferentiated (poorly differentiated)
A term used to describe tumor cells that grow uncontrollably and lack the structures and function of normal cells. Alternatively, well-differentiated tumor cells resemble normal cells, and tend to grow and spread at a slower rate than the undifferentiated (poorly differentiated) tumor cells.

Vaso-intestinal peptide (VIP)
A hormone found in the pancreas, intestine, and central nervous system. It stimulates the release of electrolytes and water by the intestinal mucosa.

Von Hippel-Lindau syndrome (VHL)
A rare genetic condition that causes tumors and cysts to grow in certain parts of the body like the brain, spinal cord, eyes, inner ear, adrenal glands, pancreas, kidney, and reproductive tract. These tumors are usually noncancerous but some can be. People with VHL syndrome have an increased risk of developing certain types of cancer, especially kidney cancer and pancreatic cancer.

X-ray therapy
A type of radiation therapy that uses high-energy radiation from X-rays to kill cancer cells and shrink tumors.

Yttrium-90 (Y-90)
A radioactive substance that can be combined with a protein to target somatostatin receptors. It releases radiation and kills the tumor cells.

Zollinger-Ellison syndrome
A disorder in which tumors produce large amounts of gastrin. It can lead stomach ulcers, esophageal reflux (when acid or bile flows into the food pipe and irritates the lining), and diarrhea. It results from the overproduction of stomach acid caused by rare neuroendocrine tumors.


IPSEN
Innovation for patient care
One of the highest volume centers in the country, the University of Chicago Medicine Neuroendocrine Tumor (NET) Program offers unique therapy options for even the most advanced cancers. We offer:

• A multidisciplinary program consisting of nationally recognized experts who specialize in diagnosing and treating all forms of NETs.

• A multidisciplinary in-person and virtual clinic that allows you to be seen by our oncologists and surgeons at the same time.

• A dedicated NET nurse navigator to guide you through the program and facilitate your treatment plan in collaboration between specialists.

• The most advanced surgical techniques, including minimally invasive/robotic procedures and complex approaches to remove and destroy NETs that have spread to the liver.

• Leading-edge technologies like precision-enhancing navigation-controlled ablation of liver tumors and Peptide Receptor Radionuclide Therapy (PRRT), a systemic, targeted approach that delivers radiation to NET cells without damaging other organs.

• The only medical cyclotron in the region for creating novel radiotracers for NETs, which helps create next-generation PRRT treatments in-house.

• Molecular profiling of NETs allowing for a personalized approach using therapies that work best on your tumor.

• One of the most experienced genetic counseling programs in the country to treat patients with NETs linked to hereditary conditions.

• Researchers conducting the latest studies on NETs, both in the laboratory and the clinic.

Our Multidisciplinary Neuroendocrine Tumor Board meets regularly to discuss complex cases.
We offer a large spectrum of treatment options for our Neuroendocrine Tumors patients.

**NETs TREATMENT OPTIONS**

- Surgery (including aggressive debulking)
- Systemic and targeted immunotherapy
- Clinical trials
- Liver-directed interventional therapies
- Localized and systemic radiation (PRRT)

**Understanding Neuroendocrine Tumors**
Visit [UChicagoMedicine.org/NETs](http://UChicagoMedicine.org/NETs) to watch video

**Research areas of focus and impact**
- Population research
- Translational research
- Cancer genetics and immunotherapy
- New treatments, early phase clinical trials

[UChicagoMedicine.org/NETs](http://UChicagoMedicine.org/NETs)
Recognized as an NCI Designated Comprehensive Cancer Center

An official cancer center designation by the National Cancer Institute (NCI) is the highest federal rating a cancer center can achieve. It’s the gold standard for cancer programs and is bestowed upon the nation’s top cancer centers in recognition of their innovative research and leading-edge treatments. UChicago Medicine has had this prestigious designation for nearly 50 years.

In addition to this NCI designation, UChicago Medicine is also recognized for the comprehensive nature of our research, care, education and community outreach programs. We are one of only two institutions in the state of Illinois — and 51 in the United States — to be recognized as a comprehensive cancer center.

Meet the Neuroendocrine Tumors Team

Xavier Keutgen, MD
Endocrine Surgery

Chih-Yi Liao, MD
Hematology and Oncology (Cancer)

Blase Polite, MD
Hematology and Oncology (Cancer)

Daniel Appelbaum, MD
Nuclear Medicine

Osmanuddin Ahmed, MD
Vascular and Interventional Radiology

Namrata Setia, MD
Pathology

Seeking the opinion of an expert can ease your mind and help you feel more secure in the decisions you are making. At UChicago Medicine, we offer both on-site and remote second opinions. In addition to recommending standard therapies, our physicians may also offer innovative treatment options not widely available at most hospitals, including clinical trials that may be right for you.

To learn more, call 1-855-702-8222 or visit UChicagoMedicine.org/cancer-appointment.

Our dedicated nurse navigator will guide you through the program and facilitate your treatment plan in collaboration with our multidisciplinary team.

To make an appointment, call 800-824-0200 or email NETS@uchospitals.edu
Find. Fight. Follow.™

It begins with a passion for innovation. For people. For making a difference. At Progenics Pharmaceuticals, Inc., a Lantheus company, we Find, Fight and Follow disease to improve outcomes and lives.

We are an established leader in the development, manufacturing and commercialization of pioneering diagnostic and therapeutic products, and artificial intelligence (AI) solutions.

Because I promised my granddaughter more days like this.

Our commitment starts here.
Find. Fight. Follow.™
Pheo and para are caused by inherited genetic mutations more than any other cancer.

Although rare, as many as 130,000 people are living with pheo or para in the US.

To learn more about pheo and para, tips for talking to your doctor, and community resources, visit KnowPheoPara.health
Important Safety Information and Indication

- XERMELO may cause constipation which can be serious. You should stop taking XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops. Talk to your doctor if you have these symptoms.
- The most common side effects of XERMELO include nausea, headache, increase in liver enzymes, depression, flatulence, decreased appetite, swelling of your hands and feet, fever, abdominal pain, and constipation.
- Talk to your doctor about all medications you are taking as some may interact with XERMELO.
- XERMELO is not recommended if you have moderate or severe liver impairment.

Indication

XERMELO is a prescription pill, used along with somatostatin analog (SSA) therapy, for Carcinoid Syndrome diarrhea in adults who are not adequately controlled by SSA therapy.
We’re Here to Help

Did you know TerSera Therapeutics has a Personalized Nursing Support Program?

Do you have questions about Carcinoid Syndrome Diarrhea?

TerSera’s Nursing Support Program connects patients who have carcinoid syndrome diarrhea (CSD) to a dedicated, consistent Clinical Nurse Educator (CNE) who specializes in neuroendocrine tumors and CSD.

Your CNE can provide you with disease and nutrition education. Learn about the relationship between your diet and CSD, understand the role of hormones, including serotonin, and get advice on finding CSD friendly foods -- you’ll receive a FREE nutrition and recipe guide!

Sign up now to get the most out of your treatment with TerSera’s Personalized Nurse Support Program.

Call, visit, or scan to get started.

www.theNETnurse.com

844-344-4035

XERMELO® is a registered trademark of TerSera Therapeutics LLC.
©2022 TerSera Therapeutics LLC. All rights reserved.
XER-P-0335 v2 (06/2022)
Medication Support Nurse Program
A resource for patients prescribed Somatuline Depot and enrolled in IPSEN CARES

Individualized Support Services Provided by an IPSEN CARES Nurse Include:

- Disease state and therapy education, consistent with the US Prescribing Information
- Injection Experience
- Coordination of Nurse Home Health Administration services and HCP injection training, if appropriate
- Identification of potential gaps in care

The Medication Support Nurses are available from M-F, 8 am - 8 pm ET.

What is SOMATULINE® DEPOT (lanreotide) Injection?

SOMATULINE DEPOT is a prescription medicine used in adults for:

- the long-term treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiation, or for whom surgery and/or radiotherapy is not an option; the goal to treatment in acromegaly is to reduce growth hormone (GH) and insulin growth factor-1 (IGF-1) levels to normal;
- the treatment of a type of cancer known as neuroendocrine tumors, from the gastrointestinal tract or the pancreas (GEP-NETs) that has spread or cannot be removed by surgery; and
- the treatment of carcinoid syndrome to reduce the need for the use of short-acting somatostatin medicine.

It is not known if SOMATULINE DEPOT is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not take SOMATULINE DEPOT if you are allergic to lanreotide.

SOMATULINE DEPOT may cause serious side effects, including:

- Gallstones
- Changes to your blood sugar (high or low blood sugar),
- Slow heart rate, and
- High blood pressure

Please see additional Important Safety Information throughout and accompanying full Prescribing Information and Patient Information.
IMPORTANT SAFETY INFORMATION (Continued)

Tell your healthcare provider (HCP) if you have any of the following symptoms:

- **Symptoms of gallstones** may include sudden pain in your upper right stomach area (abdomen), sudden pain in your right shoulder or between your shoulder blades, yellowing of your skin and whites of your eyes, fever with chills, and nausea.
- **Symptoms of high blood sugar** may include increased thirst, increased appetite, nausea, weakness or tiredness, urinating more than normal, and fruity smelling breath.
- **Symptoms of low blood sugar** may include dizziness or lightheadedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, irritability or mood changes, and hunger.
- **Symptoms of slow heart rate** may include dizziness or lightheadedness, fainting or near-fainting, chest pain, shortness of breath, confusion or memory problems, and weakness or extreme tiredness.

The most common side effects of SOMATULINE DEPOT in people with:

- **Acromegaly:** diarrhea, cholelithiasis, abdominal pain, nausea, injection-site reactions, constipation, flatulence, vomiting, arthralgia, headache, and loose stools
- **GEP-NETs:** stomach area (abdominal) pain; muscle and joint aches; vomiting; headache; pain, itching or a lump at the injection site
- **Carcinoid syndrome:** headache, dizziness, muscle spasm; side effects were generally similar to those commonly seen with GEP-NETs

SOMATULINE DEPOT may cause dizziness. If this happens, do not drive a car or operate machinery.

Tell your HCP right away if you have signs of an allergic reaction after receiving SOMATULINE DEPOT, including swelling of your face, lips or tongue; breathing problems; fainting, dizziness or feeling lightheaded (low blood pressure); itching; skin flushing or redness; rash; or hives.

Before taking SOMATULINE DEPOT, tell your HCP about all your medical conditions including if you:

- have diabetes; have gallbladder, heart, thyroid, kidney or liver problems; are pregnant or plan to become pregnant; or are breastfeeding or plan to breastfeed. It is not known if SOMATULINE DEPOT will harm your unborn baby or pass into breast milk. You should not breastfeed if you receive SOMATULINE DEPOT and for 6 months after your last dose. SOMATULINE DEPOT may affect your ability to become pregnant.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SOMATULINE DEPOT and other medicines may affect each other, causing side effects. SOMATULINE DEPOT may affect the way other medicines work, and other medicines may affect how SOMATULINE DEPOT works. Your dose of SOMATULINE DEPOT or your other medications may need to be changed. If you have diabetes, your HCP may change your dose of diabetes medication when you first start receiving SOMATULINE DEPOT or if your dose of SOMATULINE DEPOT is changed.

Especially tell your HCP if you take:

- Insulin or other diabetes medicines,
- A cyclosporine (Gengraf, Neoral, or Sandimmune), or
- Medicines that lower your heart rate, such as beta blockers.

Know the medicines you take. Keep a list of them to show your HCP when you get a new medicine.

Tell your HCP if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of SOMATULINE DEPOT. Ask your HCP.

To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information and Patient Information.

SOMATULINE DEPOT is a registered trademark of IPSEN PHARMA S.A.S.
IPSEN CARES is a registered trademark of Ipsen S.A.
©2022 Ipsen Biopharmaceuticals, Inc. March 2022 SMD-US-005112 V 2.0
NUCLEAR MEDICINE and Your Health

Nuclear medicine is a medical specialty that uses radiopharmaceuticals to diagnose, treat, and monitor diseases. Nuclear medicine and molecular imaging procedures have a long history of use.

RADIOPHARMACEUTICALS are any drugs that contain a radioactive substance. Some radiopharmaceuticals are comprised of a radioisotope attached to a targeting molecule. These can be used to diagnose, treat, or monitor disease.

RADIOISOTOPE is an atom that releases excess energy in the form of radiation; also called a radionuclide.

ALPHA AND BETA PARTICLES don’t travel very far. They are used primarily for treatment as they can damage diseased cells.

GAMMA RAYS can pass through the human body and are detected using specialized cameras, making them a useful diagnostic tool.

IMAGING AND DIAGNOSIS
Nuclear medicine diagnostics, or molecular imaging, uses radiopharmaceuticals to see how the body is functioning and to observe its chemical and biological processes. Other diagnostic imaging procedures, such as x-rays or computed tomography (CT), assist in detecting changes in physical structures.

TREATMENT
Nuclear medicine can be used to treat many diseases, such as certain types of cancer. In nuclear medicine therapy, a radiopharmaceutical is injected into a patient’s bloodstream, and binds to a specific receptor expressed on a particular tumor cell in the body. Radiation causes damage in target and nearby cells.
Radiation exists naturally in our environment. All living beings are exposed to radioactive elements every day in the air, water, plants, and even the food we eat.

**BACKGROUND RADIATION**
Humans are exposed to radiation in many forms every day, including from natural vegetation, food, air travel, and other common sources.

**AIR TRAVEL**

**VEGETATION**

**FOOD**

**MEDICAL RADIATION**
Medical radiation is used as a targeted form of treatment or for diagnosis. Nuclear medicine uses measured amounts of radiation to treat patients.

**MRI**

**MAMMOGRAM**

**PET SCAN**

**X-RAY**

**CANCER TREATMENTS**

**How Common Are Nuclear Medicine Procedures?**

Today, nuclear medicine procedures are used often, with the United States and Europe being the leaders in using this technology.

- Although the radiation levels may vary with different procedures, the goal is to minimize the amounts of radioactivity administered while still providing the highest quality diagnostic information.
- Discuss the benefits and risks of any nuclear medicine treatment or procedure with your medical provider.

MRI, magnetic resonance imaging; PET, positron emission tomography.

Visit [www.nuclearmedicineandyou.com](http://www.nuclearmedicineandyou.com) and speak to your doctor to learn more about nuclear medicine procedures.
An established radiopharmaceutical manufacturer and supplier with a proven history.

And an emerging leader in theranostics.

With a strong precision oncology drug development program.

To learn more visit www.itm-radiopharma.com

or follow-us on LinkedIn and Twitter.
ITM is proud to support the 2022 Neuroendocrine Tumor Research Foundation Virtual Education Conference

To learn more visit www.itm-radiopharma.com

or follow-us on LinkedIn and Twitter

About ITM

ITM is a radiopharmaceutical biotech company, dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. ITM is advancing a broad pipeline combining high-quality radioisotopes with targeting molecules to develop precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.

ITM isotope Technologies Munich SE, Lichtenbergstrasse 1, 85748 Garching/Munich, Germany
Crinetics Pharmaceuticals was founded in endocrine research. We focus on the discovery, development, and commercialization of much-needed therapies for rare endocrine diseases, including NETs with associated carcinoid syndrome.

Our patient-focused approach means our scientists begin the drug discovery process by talking to patients and their healthcare providers. Our goal is to understand what the needs are and how our work can achieve more effective disease control while helping improve patients’ daily lives.

**ABOUT US**

**NOW ENROLLING PARTICIPANTS**

**CRN00808-11: Open-Label Study in Patients with Carcinoid Syndrome**

This is a Phase 2 clinical research study for an investigational drug, paltusotine. The goal is to understand how the study drug affects symptoms of carcinoid syndrome. The study will consist of an 8-week treatment period followed by a 50-week extension phase for eligible patients.

“Investigational” means the study drug has not been approved by regulatory authorities like the US Food and Drug Administration (FDA) or European Medicines Agency (EMA) and can only be used for research purposes.

**WHO CAN PARTICIPATE?**

- Naïve or treated with octreotide or lanreotide
- BM and flushing criteria
- Positive SSTR expression
- Grade 1 or 2 NET

**WHAT TO EXPECT IF YOU JOIN THE STUDY**

- Receive health assessments to see if you qualify for the study
- Take the study drug once a day by mouth for the duration of your participation
- Attend study clinic visits for health assessments
- Check in with study staff 30 days after you stop taking the study drug to check your health

**TO LEARN MORE ABOUT THIS STUDY:**

CLICK HERE

Or email us at clinicaltrials@crinetics.com

Learn more about Crinetics and our groundbreaking work HERE.

**PATIENT INSIGHTS PROGRAM**

**SHARE YOUR OPINIONS**

The Crinetics Patient Insights Program (PIP) gives patients an opportunity to contribute to drug development through important market research. If you are living with carcinoid syndrome stemming from neuroendocrine tumors (NETs), we’d love to hear from you. As a participant, you would play a key role by:

- Sharing your perspectives via online surveys, virtual calls, and focus groups
- Taking part in discussions around patient needs, current treatments, and your daily life
- Contributing to the vital dialog we are committed to continue with people like you

Patients in the PIP are contacted 4-6 times per year to provide opinions and insights regarding their medical condition. PIP members are compensated a fair market value for their time.

Learn more about the Patient Insights Program at Crinetics and sign up HERE or email us at patientinsights@crinetics.com.

**PATIENT LEADERSHIP COUNCIL**

**YOUR VOICE MATTERS**

The Patient Leadership Council (PLC) for carcinoid syndrome due to NETs is also a key way Crinetics practices a patient-focused approach to drug development. This forum gives patients a seat at the table, with opportunities to share their perspectives and first-hand experiences on important topics relevant to their condition, such as:

- The journey to diagnosis
- Treatment experiences
- Educational needs
- Unmet needs regarding NETs
- Clinical trial experiences and feedback

Those chosen for the PLC serve for 12 months and attend a monthly video conference call. Members are compensated a fair market value for their time.

Email patientadvocacy@crinetics.com to learn more.
Thank you for attending the 2022 KNOW YOUR NETs Virtual Patient and Caregiver Conference. We would like to gratefully acknowledge all of our speakers for their presentations, all panelists for their insight, and all volunteers for their knowledge and help to make this conference a reality.

Educational Support

Thank you to the following sponsors for their generous support:

- UChicago Medicine
  Comprehensive Cancer Center
- Progenics Pharmaceuticals
- LANTHEUS
- IPSEN
- TerSera therapeutics
- Advanced Accelerator Applications
- Crinetics Pharmaceuticals
- itm
- HUTCHMED

Find videos of this patient and caregiver education conference and others like it at:

YouTube @NETRF

Connect with us and other patients, caregivers, and family members online:

@CureNETs @NETRF

617.946.1780 info@netrf.org netrf.org